recurrent/metastatic HPV16-positive head and neck cancerHPV16-positive recurrent/metastatic oropharyngeal cancerpeltopepimut-Scemiplimab
…d with cemiplimab alone as first-line or second-line therapy in recurrent/metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint was the objective response rate …